Calidi Biotherapeutics (CLDI) Competitors $1.60 +0.03 (+1.91%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.60 +0.00 (+0.31%) As of 09/5/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLDI vs. FNCH, ABP, AIMD, ATNF, LEXX, MTEX, EDSA, SYBX, LSB, and LPCNShould you be buying Calidi Biotherapeutics stock or one of its competitors? The main competitors of Calidi Biotherapeutics include Finch Therapeutics Group (FNCH), Abpro (ABP), Ainos (AIMD), 180 Life Sciences (ATNF), Lexaria Bioscience (LEXX), Mannatech (MTEX), Edesa Biotech (EDSA), Synlogic (SYBX), LakeShore Biopharma (LSB), and Lipocine (LPCN). These companies are all part of the "pharmaceutical products" industry. Calidi Biotherapeutics vs. Its Competitors Finch Therapeutics Group Abpro Ainos 180 Life Sciences Lexaria Bioscience Mannatech Edesa Biotech Synlogic LakeShore Biopharma Lipocine Finch Therapeutics Group (NASDAQ:FNCH) and Calidi Biotherapeutics (NYSE:CLDI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations. Which has more risk and volatility, FNCH or CLDI? Finch Therapeutics Group has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, Calidi Biotherapeutics has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Is FNCH or CLDI more profitable? Calidi Biotherapeutics' return on equity of 0.00% beat Finch Therapeutics Group's return on equity.Company Net Margins Return on Equity Return on Assets Finch Therapeutics GroupN/A -69.14% -26.92% Calidi Biotherapeutics N/A N/A -344.45% Does the media refer more to FNCH or CLDI? In the previous week, Finch Therapeutics Group had 1 more articles in the media than Calidi Biotherapeutics. MarketBeat recorded 1 mentions for Finch Therapeutics Group and 0 mentions for Calidi Biotherapeutics. Calidi Biotherapeutics' average media sentiment score of 0.00 beat Finch Therapeutics Group's score of -1.00 indicating that Calidi Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Finch Therapeutics Group Negative Calidi Biotherapeutics Neutral Do insiders & institutionals have more ownership in FNCH or CLDI? 21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by insiders. Comparatively, 6.7% of Calidi Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, FNCH or CLDI? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFinch Therapeutics GroupN/AN/A-$74.75M-$8.82-1.44Calidi BiotherapeuticsN/AN/A-$29.22MN/AN/A SummaryFinch Therapeutics Group beats Calidi Biotherapeutics on 5 of the 8 factors compared between the two stocks. Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLDI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDI vs. The Competition Export to ExcelMetricCalidi BiotherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$5.48M$290.97M$5.79B$21.35BDividend YieldN/AN/A6.71%3.50%P/E RatioN/AN/A76.0829.63Price / SalesN/A474.43460.9349.11Price / CashN/A22.4436.9624.54Price / Book-0.6910.9411.484.55Net Income-$29.22M-$111.61M$3.29B$999.70M7 Day Performance-3.03%2.42%1.27%0.58%1 Month Performance-74.11%2.41%7.94%5.66%1 Year Performance-88.41%-14.20%62.93%17.40% Calidi Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDICalidi Biotherapeutics0.6721 of 5 stars$1.60+1.9%N/A-88.3%$5.48MN/A0.0038FNCHFinch Therapeutics Group0.4783 of 5 stars$12.25-3.6%N/A-3.9%$19.67MN/A-1.39190Short Interest ↑Gap UpABPAbproN/A$0.25+1.1%$4.00+1,532.7%N/A$19.43M$180K0.0015Positive NewsAIMDAinos0.4133 of 5 stars$3.80-7.5%N/A+22.5%$19.14M$20K0.0040News CoverageAnalyst UpgradeShort Interest ↑Gap DownATNF180 Life Sciences0.3057 of 5 stars$3.10+0.8%N/A+24.1%$18.72MN/A-0.217Gap UpLEXXLexaria Bioscience2.9195 of 5 stars$0.89-4.7%$4.00+351.6%-68.8%$18.17M$460K-1.327Short Interest ↑Gap DownMTEXMannatech0.4191 of 5 stars$8.85-3.6%N/A+27.3%$17.45M$117.87M-4.34250Positive NewsShort Interest ↑Gap UpEDSAEdesa Biotech1.2708 of 5 stars$2.40-1.2%$5.00+108.3%-42.7%$17.10MN/A-1.8220SYBXSynlogicN/A$1.46flatN/A-0.5%$17.08M$10K-18.2580Positive NewsLSBLakeShore Biopharma1.4754 of 5 stars$0.80-2.2%N/A-81.0%$16.88M$85.67M0.00773Positive NewsShort Interest ↓Gap DownLPCNLipocine3.2753 of 5 stars$3.01-2.9%$9.00+199.0%-22.7%$16.80M$11.20M-3.4610News Coverage Related Companies and Tools Related Companies Finch Therapeutics Group Competitors Abpro Competitors Ainos Competitors 180 Life Sciences Competitors Lexaria Bioscience Competitors Mannatech Competitors Edesa Biotech Competitors Synlogic Competitors LakeShore Biopharma Competitors Lipocine Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CLDI) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredScientists Discover Untapped Energy Source in Heart of USACrash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredOdd “310F trade” doubles investor’s money in just 3 days?Have you heard of 310F? This unusual trade setup has quietly delivered one of the most consistent profit st...Eagle Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLDI Stock Alerts